title: Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.
abstract: In patients with hepatorenal syndrome (HRS), 4-hr administration of a vasopressin analog has recently been shown to benefit renal blood flow and renal function. However, long-term effects and tolerance of this treatment have not been reported. We report a case of HRS that was controlled by the vasopressin analog, terlipressin. Because HRS repeatedly relapsed when treatment was discontinued, terlipressin, 2 mg/day was administered for 67 days, until liver transplantation could be performed in a patient with normal renal function. Except for limited cutaneous necrosis at an injection point, prolonged treatment with this vasopressin analog was well tolerated.
authors.affiliation: Service d'Hépatologie, H pital Beaujon, Clichy, France.
authors.forename: N
authors.initials: N
authors.lastname: Ganne-Carrié
authors.forename: A
authors.initials: A
authors.lastname: Hadengue
authors.forename: P
authors.initials: P
authors.lastname: Mathurin
authors.forename: F
authors.initials: F
authors.lastname: Durand
authors.forename: S
authors.initials: S
authors.lastname: Erlinger
authors.forename: J P
authors.initials: JP
authors.lastname: Benhamou
mesh_terms: D000328:Adult; D005260:Female; D006530:Hepatorenal Syndrome / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D007262:Infusions, Intravenous; D016031:Liver Transplantation; D008236:Lypressin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077585:Terlipressin; D013997:Time Factors; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin